2023-alarm-clock-copy

Key clinical developments in 2023

This module is suitable for use as part of pharmacists’ continuing professional development, a key component of the revalidation process. After reading this module in the magazine or online at pharmacymagazine.co.uk, you can include it in your personal Pharmacy Magazine revalidation record.

Key facts

  • Community pharmacies in England will be able to provide clinically appropriate prescription medicines via PGDs for seven common conditions in 2024
  • The POM to P switch of tadalafil is a new treatment option for erectile dysfunction
  • Semaglutide (Wegovy) is now licensed for obesity
  • Emollient bath additives are no longer recommended in eczema (NICE update)
  • Updates in NICE UTI guidelines pave the way for pharmacist consultations as part of the Pharmacy First common conditions programme (see also first bullet point)
  • Pholcodine-containing medicines were withdrawn from the market in 2023.

Contributing author

Nicola Tyers, director, The Pharmacy Training Company and senior lecturer at Medway School of Pharmacy

Change privacy settings